Janus Henderson Group
SNDX icon

Janus Henderson Group’s Syndax Pharmaceuticals SNDX Stock Holding History

Janus Henderson Group’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$920K Hold
39,335
– – ﹤0.01% 1732
2025
Q4 		$827K Hold
39,335
– – ﹤0.01% 1772
2025
Q3 		$605K Hold
39,335
– – ﹤0.01% 1913
2025
Q2 		$368K Hold
39,335
– – ﹤0.01% 2090
2025
Q1 		$518K Hold
39,335
– – ﹤0.01% 1944
2024
Q4 		$520K Hold
39,335
– – ﹤0.01% 2013
2024
Q3 		$757K Hold
39,335
– – ﹤0.01% 1804
2024
Q2 		$808K Sell
39,335
-9,613
-20% -$201K ﹤0.01% 1733
2024
Q1 		$1.16M Buy
48,948
+22,501
+85% +$502K ﹤0.01% 1560
2023
Q4 		$572K Sell
26,447
-39
-0.1% -$599 ﹤0.01% 1925
2023
Q3 		$384K Buy
26,486
+6
+0% +$113 ﹤0.01% 2068
2023
Q2 		$554K Sell
26,480
-76
-0.3% -$1.58K ﹤0.01% 1926
2023
Q1 		$561K Buy
+26,556
New +$661K ﹤0.01% 1947
2021
Q2 		– Sell
-141,325
Closed -$3.16M – 1666
2021
Q1 		$3.16M Buy
141,325
+10,867
+8% +$246K ﹤0.01% 1101
2020
Q4 		$2.9M Buy
+130,458
New +$2.71M ﹤0.01% 1065

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Janus Henderson Group's SNDX Position: Q1 2026 in Review

Janus Henderson Group held its Syndax Pharmaceuticals (SNDX) position steady in Q1 2026 at 39,335 shares worth $920K. The position accounts for ﹤0.01% of the portfolio, ranked #1732.

Janus Henderson Group first reported a position in SNDX in Q4 2020 and has held it in 15 quarters since. The position peaked at $3.16M in Q1 2021. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Janus Henderson Group held 39,335 shares of Syndax Pharmaceuticals worth $920K as of Q1 2026.
  • Janus Henderson Group left its Syndax Pharmaceuticals share count unchanged in Q1 2026.
  • Syndax Pharmaceuticals made up ﹤0.01% of Janus Henderson Group's portfolio in Q1 2026, its #1732 holding.
  • Janus Henderson Group first reported a position in Syndax Pharmaceuticals in Q4 2020 and has held it in 15 quarters since.
  • Janus Henderson Group's Syndax Pharmaceuticals position peaked at $3.16M in Q1 2021.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.